NuvaHealth review
Six figures are published. All six are first months. The rate that follows is shown at checkout.
The verdict
NuvaHealth publishes six figures, read August 2026. Each buys one month. The ongoing rate appears at checkout. Nothing on the site states it beforehand.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Both molecules appear, injected and oral, across six priced lines. The figures span an order of magnitude. The opening one sits beside entries above a thousand dollars. Nothing distinguishes them but the number.
Who writes the prescription, and what do they see?
Treatment is arranged remotely. A prescription precedes the first shipment. The pages do not describe who writes it. The intake is not documented.
Everything is compounded and the service runs at a distance. The distinguishing feature is what the site withholds. A reader can see six prices and cannot see the price. That sequence puts the decision after the commitment rather than before it.
What happens when the dose goes up?
No line states what happens as the dose rises. That question compounds the first one. A buyer who does not know the month-two rate also does not know what it becomes at a higher dose.
What the price includes
The opening figure applies once, and NuvaHealth says so plainly. What follows it is not published anywhere a reader can reach. That is a missing fact rather than an uncertain one, and it is the seller's to supply. Two entries sit above a thousand dollars on identical terms with nothing to explain the distance. A spread that wide across six lines reads as a quote range rather than a price list.
What it claims, and what it cites
Both molecules are compounded. Neither is FDA-approved. No agency reviews them before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: The first-month limit is admitted in writing
- Strength: Four routes are listed on one page
- Strength: The outlier entries are shown, not hidden
- Limitation: No ongoing rate is published
- Limitation: The real price appears at checkout
- Limitation: No dose behavior is stated
- Limitation: No pharmacy is named
What the evidence says about this kind of treatment
The assessment above is about NuvaHealth. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader prepared to reach checkout before learning the standing rate.
- Wrong for
- A reader who wants to compare a year before entering details.
How NuvaHealth compares
| Seller | Who it suits | Go |
|---|---|---|
| FORM | Readers who already know the manufacturer price and want a named route to a prescriber | See FORM → |
 Direct Meds | Readers comfortable buying a quarter who will check the arithmetic themselves | See Direct Meds → |
| GobyMeds | Readers who can pay twelve weeks at once and want the extras inside one figure | See GobyMeds → |
More GLP-1 telehealth sellers reviews: FoundFridaysGalaGenesis HealthGet Thin MDGlam Health
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- What is the monthly price?
- Nowhere on the site. Every published figure buys a single month, and the seller directs a reader to checkout for what follows.
- Can a year be estimated?
- No. Any total assumes a standing rate the seller has never published. That is a missing fact, not an uncertain one.
- What are the four-figure entries?
- Two lines sit above a thousand dollars on the same first-month terms. They appear beside the low ones. Nothing explains the distance.